Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical outcomes after swicth from etanercept to etanercept biosimilar (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthrits:- DANBIO registry study

Trial Profile

Clinical outcomes after swicth from etanercept to etanercept biosimilar (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthrits:- DANBIO registry study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Joint disorders; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 28 Feb 2020 Results evaluating hepatobiliary adverse events after the treatment of Biosimilar Etanercept compare to Etanercept in more then 5000 patients, published in the Annals of the Rheumatic Diseases
    • 05 Nov 2018 Results assessing treatment outcomes in Etanercept-treated patients who switched to the Biosimilar Etanercept or maintained Etanercept, published in the Annals of the Rheumatic Diseases
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top